Clinical Trial

GM-CSF With Post-Transplant Cyclophosphamide

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Given the increased number of HLA-mismatched haploidentical transplantation with post-transplant cyclophosphamide performed each year and the high risk of infectious complications associated with this type of transplant, the investigators suggest that GM-CSF administration post-infusion of T-replete haploidentical stem cells and post-transplant cyclophosphamide can yield similar count recovery rates to G-CSF with a potential of lowering risk of infectious complications.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2020-01-17; most recent amendment 2026-04-15.
Status change: Not Yet Recruiting → Recruiting 2020-07-24
Trial Details
NCT Number NCT04237623
Lead Sponsor Northside Hospital, Inc.
Conditions Transplant-Related Hematologic Malignancy
Enrollment 38 participants
Start Date 2020-05-18
Primary Completion 2026-09-18 (estimated)
Study Completion 2026-09-18 (estimated)
Updated on ClinicalTrials.gov 2026-04-16